Biomaterials-Based Infection Vaccine Technology Could Help in Covid-19 Immunization

USA: Corona-Vaccine Biomaterials-Based Infection Vaccine Technology Could Help in Covid-19 Immunization

2020-08-25 From Benjamin Boettner

To confront the many challenges that infectious diseases pose to mankind head-on, a multi-disciplinary team of bioengineers, materials-scientists and immunologists at Harvard’s Wyss Institute has developed a broadly deployable biomaterials-based infection vaccine technology called “Omnivax.”

To create vaccine formulations against the Sars-Cov-2 virus, the team included combinations of different antigens derived from the virus’ Spike protein complex in the modular vaccine.(Source: Wyss Institute at Harvard University) — To create vaccine formulations against the Sars-Cov-2 virus, the team included combinations of different antigens derived from the virus’ Spike protein complex in the modular vaccine.
(Source: Wyss Institute at Harvard University)

Cambridge/USA — Inspired by a fundamentally new cancer vaccine approach created by David Mooney’s group in the immuno-materials platform, a multi-disciplinary team of scientists has developed a novel vaccine technology.

The vaccine platform approach is rooted in the idea that antigens, when they are incorporated together with immune-activating adjuvants in a longer-lived biomaterial scaffold that concentrates immune cells at the site of vaccination, can be presented to the immune system in a more controlled and sustained way than when merely provided transiently in soluble form. As a result of this, the immune system’s protective responses can be more effective and prolonged.

Soon after Covid-19 started to spread across the globe, devastating millions of lives and pushing the health systems and economies of many countries to their limits, Mooney’s team, which had previously focused on other infectious diseases, pivoted and used their Omnivax platform to generate vaccines against the Sars-Cov-2, the virus responsible for the pandemic. Mooney is a Wyss core faculty member and the Robert P. Pinkas Family Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences (Seas).

It is widely accepted that a safe and effective vaccine that creates broad immunity against the coronavirus, and can be made quickly and distributed almost universally will be critical to address this pandemic. Experts estimate that it might take around 12 to 18 months to achieve this goal, which still would be record time for delivering a vaccine — and the race is on in many corners of the world.

In the modular assembly of Sars-Cov-2-specific Omnivax vaccines, the team combined a scaffold-forming mesoporous silica biomaterial (top right), the dendritic cell-recruiting factor GM-CSF (bottom left), an immune-stimulating adjuvant (bottom right), and combinations of specific antigens derived from the host cell-binding spike structure on the surface of Sars-Cov-2 (top left).(Source: Wyss Institute at Harvard University) — In the modular assembly of Sars-Cov-2-specific Omnivax vaccines, the team combined a scaffold-forming mesoporous silica biomaterial (top right), the dendritic cell-recruiting factor GM-CSF (bottom left), an immune-stimulating adjuvant (bottom right), and combinations of specific antigens derived from the host cell-binding spike structure on the surface of Sars-Cov-2 (top left).
(Source: Wyss Institute at Harvard University)

Using Omnivax’s fast and effective vaccine strategy, the team created a collection of vaccines against the Covid-19-causing Sars-Cov-2 virus. Their approach is highly modular, based on the simple and rapid combination of a mesoporous silica material, an adjuvant, the dendritic cell-recruiting factor GM-CSF, and one or more antigen(s). Many different antigens and adjuvants can be combined in a plug-and-play fashion.

The researchers believe that Omnivax vaccines with their unique structure and mechanism could provide protection against a number of infectious diseases caused by uncontrollable viral and bacterial pathogens, including those that will be responsible for forthcoming epidemics. Researchers believe it may have great potential to become a vaccine technology of the future.

The vaccine candidate developed by Sanofi in partnership with GSK is based on the recombinant protein-based technology combined with GSK’s pandemic adjuvant system. (Deposit Photos )

The Wyss Institute recognized the potential of the technology early on, years before Covid-19 changed our world in a matter of a few months, and had designated the Omnivax platform technology “Institute Project” status. This prioritization is reserved for its most prestigious projects to accelerate their translational path to becoming the main assets of future startup companies with special business and technology development support.

The uniqueness of the Omnivax approach is based on its design that directs dendritic cells, the key orchestrators of pathogen-directed and other immune responses, to be actively recruited into the porous scaffold structure. Once in the structure, they are reprogrammed more effectively against a pathogen by specific antigen/adjuvant combinations. The trafficking of the dendritic cells can occur for the duration of the vaccine, allowing a significant multiplication of the resultant immune response.

This is the first report that highlights that Sars-Cov-2 may target the PBC of the brainstem that controls respiration and causes respiratory collapse of Covid-19 patients. (Source: CSIR- IICB)

Then, just like after their normal activation in the body, the reprogrammed dendritic cells migrate to nearby lymph nodes where they initiate a complex immune response involving both, fast-acting T cells and antibody-producing B cells that attack pathogens using different mechanisms. By allowing the activation of dendritic cells to be more prolonged, the Omnivax approach essentially adds a fourth dimension, namely time, to the three dimensions of the physical vaccine structure, which sets it apart from other vaccine approaches, and generates significantly more robust and durable responses than standard vaccines.

Vaccines against Sars-Cov-2 and beyond

Taking advantage of the modular nature of the Omnivax approach, the Wyss team generated their Sars-Cov-2 vaccines incorporating different combinations of viral antigens in combination with a general immune-activating adjuvant, and recently reported their preliminary findings in a bio Rxiv paper. After receiving virus-specific antigens, it took the team merely three days to complete vaccines that were ready for injection.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

A single injection of the vaccines into mice stimulated the rapid production of significant levels of antibodies that were specific to the viral antigens, and maintained for at least 96 days. In addition, the researchers analyzed blood sera from the vaccinated animals, the liquid component of blood which contains antibodies previously made by the immune system’s B cells like, in this case, Sars-Cov-2-directed antibodies.

More than 280 Covid-19 vaccines are under development across the globe, out of which only 6 vaccines are in the clinical development phase in China. (Deposit Photos )

In in vitro neutralization assays, the sera could prevent the infection of cultured cells by a Sars-Cov-2 pseudovirus, which is commonly used in coronavirus research as a key step to analyze the protective function of a vaccine. The team is currently pursuing studies in which they aim to protect animal models that are challenged with the actual coronavirus to confirm the efficacy of the vaccines.

Besides these first promising observations on the Covid-19 Omnivax vaccines, the team’s new approach could also provide protective solutions for many common unmet infectious diseases that have been threatening people in different environments.

(ID:46826649)